| Title |
Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability
|
|---|---|
| Published in |
Journal of Neurology, July 2015
|
| DOI | 10.1007/s00415-015-7852-y |
| Pubmed ID | |
| Authors |
Hélène Zéphir, Raphaël Bernard-Valnet, Christine Lebrun, Olivier Outteryck, Bertrand Audoin, Bertrand Bourre, Sophie Pittion, Sandrine Wiertlewski, Jean Christophe Ouallet, Jean-Philippe Neau, Jonathan Ciron, Pierre Clavelou, Romain Marignier, David Brassat |
| Abstract |
Neuromyelitis optica (NMO) is a life-threatening disease without any validated treatment strategy. Recent retrospective studies suggested the efficacy of B cell depletion without any distinction between first-line or rescue therapy. To assess whether rituximab as first-line therapy in NMO could efficiently control the occurrence of relapses. A retrospective analysis of NMO patients from NOMADMUS network found 32 patients receiving rituximab as first-line therapy. Main measures were number of relapse-free patients, changes in the annualized relapse rate (ARR), and changes in the EDSS. Tolerance was reported. At baseline, NMO patients were 45 ± 12.1 years old, with a sex ratio of 5.4, and 87.5 % of them had AQP4 antibodies. The median disease duration was 6.5 months (1-410), the mean EDSS was 5.8 ± 2.4 and the mean ARR was 3.8 ± 4.3. After rituximab with a mean follow-up of 28.7 ± 21 months, twenty-seven patients (84.3 %) were relapse free. Patients presented a 97 % decrease of ARR (p = 0.00001). EDSS decreased significantly to 3.9 ± 2.6 (p = 0.01). No relevant side effect was noted. New retrospective data are presented on RTX use in NMOSD. When used as first-line therapy RTX is highly effective and well tolerated. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 2% |
| Unknown | 65 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 8 | 12% |
| Student > Master | 8 | 12% |
| Researcher | 7 | 11% |
| Student > Bachelor | 7 | 11% |
| Student > Doctoral Student | 6 | 9% |
| Other | 12 | 18% |
| Unknown | 18 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 41% |
| Neuroscience | 7 | 11% |
| Immunology and Microbiology | 4 | 6% |
| Agricultural and Biological Sciences | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 18 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2017.
All research outputs
#13,092,812
of 22,818,766 outputs
Outputs from Journal of Neurology
#2,723
of 4,476 outputs
Outputs of similar age
#118,615
of 264,065 outputs
Outputs of similar age from Journal of Neurology
#31
of 62 outputs
Altmetric has tracked 22,818,766 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,476 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,065 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.